Role of transporters in the drug excretion and its significance in new drug development

Abstract

Abstract: This review is mainly concerned about the effects of drug transporters on drug excretion and the possibility in the development and clinical application of new drugs.The understanding of the properties of transporters enables us to develop novel drugs , which can increase the site-directional drug delivery , or avoid the distribution to other organs , thereby increase the therapeutic effects and reduce the chance of toxic effects.Furthermore , the research of drug transporter- mediated drug-drug interactions and enterohepatic cycle , is able to guide us a more reasonable , safe and effective clinical medication.It is well accepted in recent years that the pharmacokinetic properties of a new drug should be studied in its early stage of development.Additionally , high-through screening system established on transporters is bound to be an effective tool to accelerate the development of new drugs.

Key words: drug transporter, hepatic biliary excretion, renal excretion, drug targeting

CLC Number:

R969.1

WANG Lei , LI Ning , CHEN Xi-jing. Role of transporters in the drug excretion and its significance in new drug development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 448-454.

References

[1] Sekine T, Miyazaki H, Endou H.Molecular physiology of renal organic anion transporters[J].Am J Physiol Renal Physiol, 2006, 290(2):F251-F261.
[2] Choudhuri S, Klaassen CD.Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP)efflux transporters[J].Int J Toxicol,2006, 25(4):231-259.
[3] Sweet DH.Organic anion transporter (Slc22a)family members as mediators of toxicity[J].Toxicol Appl Pharmacol, 2005, 204(3):198-215.
[4] Shitara Y, Horiea T, Sugiyama Y.Transporters as a determinant of drug clearance and tissue distribution[J].Eur J Pharm Sci, 2006, 27(5):425-446.
[5] Funk C, Ponelle C, Scheuermann G, et a1.Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity:in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep)in the rat[J].Mol Pharmacol, 2001, 59(3):627-635.
[6] Wang DS, Kusuhara H, Kato Y, et al.Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin[J].Mol Pharmacol, 2003, 63(4):844-848.
[7] Vavricka SR, Van Montfoort J, Ha HR, et a1.Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver[J].Hepatology, 2002, 36 (1):164-172.
[8] Kajinami K, Takekoshi N, Saito Y.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev, 2003, 21(3):199-215.
[9] Dominguez MF, Macias RI, Izco-Basurko I, et al.Low in vivo toxicity of a novel cisplatin-ursodeoxy cholic derivative (Bamet-UD2).with enhanced cytostatic activity versus liver tumors[J].J Pharmacol Exp Ther, 2001, 297 (3):1106-1112.
[10] Nakanishi T, Tamai I, Takaki A, et al.Cancer cell-targeted drug delivery utilizing oligopeptide transport activity [J].Int J Cancer, 2000, 88(2):274-280.
[11] Yamada I, Fukunari A, Osajima T, et al.Pharmacokinetics pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man[J].Nucleosides Nucleotides Nucleic Acids, 2004, 23(8 9):1123-1125.
[12] Sai Y, Kato Y, Nakamura K, et al.Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700[J].J Pharm Sci, 2006, 95 (2):336-347.
[13] Marchetti S, Mazzanti R, Beijnen JH, et al.Concise review:Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-gly coprotein)[J].Oncologist, 2007, 12(8):927-941.
[14] Shitara Y, Hirano M, Sato H, et a1.Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2 OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analy sis of the mechanism of the clinically relevant drugdrug interaction between cerivastatin and gemfibrozil[J].J Pharmacol Exp Ther, 2004, 311(1):228-236.
[15] Farkas D, Greenblatt DJ.Influence of fruit juices on drug disposition:discrepancies between in vitro and clinical studies[J].Expert Opin Drug Metab Toxicol, 2008, 4 (4):381-393.
[16] 范岚, 谢海棠, 周宏灏.中西药合用治疗肿瘤的相互作用及其机制探讨[J].中国临床药理学与治疗学,2007, 12(2):134-139.
[17] 毛晓琴, 谢海棠, 周宏灏.多药耐药蛋白和CYP3A4介导的中草药-西药相互作用[J].中国临床药理学与治疗学, 2007, 12(7):728-734.
[18] Yang XX, Hu ZP, Duan W, et a1.Drug-herb interactions: eliminating toxicity with hard drug design[J].Curr Pharm Des, 2006, 12(35):4649-4664.
[19] Huang SM, Strong JM, Zhang L, et al.New era in drug interaction evaluation:US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process[J].J Clin Pharmacol, 2008, 48(6):662-670.
[20] Huang SM, Temple R, Throckmorton DC, et al.Drug interaction studies:study design, data analysis, and implications for dosing and labeling[J].Clin Pharmacol Ther, 2007, 81(2):298-304.
[21] Hammerle SP, Rothen RB, Kramer SD, et al.P-Gly coprotein in cell cultures:a combined approach to study expression, localisation, and functionality in the confocal microscope[J].Eur J Pharm Sci, 2000, 12(1):69-77.
[22] 周昕.药物吸收体外研究方法的概述[J].中国临床药理学与治疗学, 2006, 11(4):379-384.
[23] Chang C, Swaan PW.Computational approaches to modeling drug transporters[J].Eur J Pharm Sci, 2006, 27(5): 411-424.
[24] 马秉亮, 吴玉林, 刘国卿.P-gp 及对抗P-gp 介导多药耐药的研究现状[J].中国临床药理学与治疗学,2006, 11(1):14-21.
[25] DemelMA, Schwaha R, Kr?mer O, et a1.In silico prediction of substrate properties for ABC-multidrug transporters[J].Expert Opin Drug Metab Toxicol, 2008, 4(9):1167-1180.